Skip to main content

Advertisement

Table 3 Frequency of adverse events (only for incidence ≥ 10% in one or more vaccination groups)

From: Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study

Patients in populationTotal (n = 37)
n (%)
With one or more adverse events35 (94.6)
With no adverse events2 (5.4)
Injection site pain23 (62.2)
Injection site erythema17 (45.9)
Injection site swelling16 (43.2)
Fatigue11 (29.7)
Nausea7 (18.9)
Diarrhoea5 (13.5)
Dyspnoea5 (13.5)
Nasopharyngitis5 (13.5)
Arthralgia4 (10.8)
Back pain4 (10.8)
Cough4 (10.8)
Dizziness4 (10.8)
Pyrexia4 (10.8)